{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975064",
  "id": "02975064",
  "pages": 15,
  "price_sensitive": true,
  "date": "20250731",
  "time": "0941",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mcb3f5d9ssqb.pdf",
  "summary": "### **Imugene Limited (ASX: IMU) \u2013 Quarterly Report (Appendix 4C) Summary**  \n\n#### **Clinical & Operational Highlights:**  \n- **Azer-cel Phase 1b Trial:**  \n  - 6 Complete Responses (CR), 3 Partial Responses (PR) (75% ORR).  \n  - First patient remains cancer-free at 15 months post-treatment.  \n  - Expanding to CAR T-na\u00efve patients with rare B-cell lymphomas.  \n  - FDA Type B meeting planned for Q4 CY25 to discuss pivotal trial design.  \n- **onCARlytics (OASIS Trial):** First IV dose level cleared in Phase 1 solid tumor study.  \n- **PD1-Vaxx Neo-POLEM Trial:** First Australian patient dosed in Phase 2 colorectal cancer study.  \n- **Patents:** US patent issued for onCARlytics (exp. 2038); PD1-Vaxx patent extended to 2042.  \n\n#### **Corporate & Financial Updates:**  \n- **Capital Raising:**  \n  - **$22.5M Placement** completed at $0.33/share.  \n  - **$15M SPP pending** (same terms, incl. attaching options).  \n- **Cash Position (30 June 2025):** $21.93M (down from $36.25M prior quarter).  \n- **Post-Qtr Cash Inflows:**  \n  - **$5.8M R&D tax refund** received (FY24).  \n- **Cash Burn:** Net operating outflow of **$12.98M** (23% QoQ reduction).  \n- **Runway:** Funding expected to extend into 2027 (post-SPP & option exercises).  \n\n#### **Key Appendix 4C Data:**  \n- **R&D Spend:** $8.93M (68% of total operating costs).  \n- **Staff Costs:** Reduced to <23 FTEs (from ~80\u2013100) with ~40% cost savings.  \n\n**No material non-clinical/financial updates identified.**",
  "usage": {
    "prompt_tokens": 7118,
    "completion_tokens": 437,
    "total_tokens": 7555,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T23:48:37.130234"
}